Haas Jason 4

What Happened
Jason Haas, a director of Ligand Pharmaceuticals (LGND), was granted equity awards on June 5, 2026. The Form 4 shows two award entries: 836 shares (acquisition code A) and 2,938 derivative shares (acquisition code A) — a total of 3,774 RSUs. Each line is reported at an acquisition price of $0.00 on the Form 4 (typical for RSU grants), so the filing lists $0 total paid.

Key Details

• Transaction date: 2026-06-05; Form 4 filed 2026-06-09 (filed within the usual 2-business-day window).
• Reported items: 836 RSUs (direct award) and 2,938 RSUs reported as derivative/contingent — total 3,774 RSUs. Price shown: $0.00.
• Shares owned after transaction: not specified in the filing.
• Footnotes: grants are RSUs awarded by the Board at the annual meeting. Vesting: fully vests on the earlier of (A) the next annual meeting following the grant or (B) the first anniversary of the grant date.
• Transaction code: A = Award/Grant.

Context
These are time-based equity awards (RSUs), not open-market purchases or sales. The derivative line means those RSUs are contingent rights to receive shares upon vesting. Such grants are routine compensation for directors and do not, by themselves, indicate buying or selling behavior in the market.